CoRIS Cohort
Our
Our research is organised around areas aiming to respond to real needs of people living with HIV (PLWH).
Continued innovation in HIV treatments, newly emerging concomitant diseases and changing epidemiological trends make it necessary to conduct further research on the clinical features of HIV infection.
This is why our research prioritises the areas whose clinical impact is higher, namely:
DIAGNOSTIC DELAY, DISEASE
PROGRESSION, RESPONSE TO ART
AND MORTALITY.
Antiretroviral treatment has significantly improved the prognosis of PLWH. They can now live with HIV as a chronic illness, and their life expectancy is closer to that of the general population.
Since mortality among PLWH is fortunately less and less common, it is essential to study its incidence and distribution with data from multicentre cohorts that collaborate by means of unified data collection procedures.
AGEING AND
COMORBIDITIES
Antiretroviral treatment has had a major impact on the morbidity and mortality patterns among PLWH. In fact, research now focuses on studying non-AIDS defining events (NADEs), which are concomitant diseases in PLWH. Epidemiological data on NADEs are still scarce, so more information is needed in order to analyse in depth how they work.
CO-INFECTIONS WITH HEPATITIS C
VIRUS (HCV), HEPATITIS B VIRUS (HBV),
PAPILLOMAVIRUS (HPV) AND OTHER SEXUALLY
TRANSMITTED
INFECTIONS (STIs)
In Spain, between 20% and 25% of PLWH have an active Hepatitis C infection (HCV), which is the main risk factor for disease. Constant changes in the clinical features of HIV and HCV require ongoing follow-up and tracking.
Furthermore, people living with HIV and Hepatitis B infection (HBV) may have higher liver-related mortality risk as opposed to patients who only have HBV. On a different note, High Risk Human Papillomavirus (HR-HPV) and HIV co-infection is very common among males who have sex with males (MSM). In our country, there is not much information to this effect, but thanks to our network collaborative research, interesting initiatives are appearing to improve diagnosis and treatment of anal HPV infection and anal intraepithelial neoplasia.
HIV DRUG RESISTANCE
AND MOLECULAR
EPIDEMIOLOGY
CoRIS provides data on drug resistance among newly diagnosed HIV patients. This information offers guidance to decide on the best treatment option for them. Drug resistance data and molecular epidemiology descriptions are key to developing public health prevention measures to curb HIV spread and transmission.
Partners
